Tenon Medical (TNON) Projected to Release Earnings on Thursday

Tenon Medical (NASDAQ:TNON) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Tenon Medical to post earnings of ($4.2250) per share and revenue of $1.55 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Tenon Medical (NASDAQ:TNON) last posted its earnings results on Thursday, August 13th. The company reported ($12.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.40) by ($3.95). The company had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.54 million. Tenon Medical had a negative return on equity of 907.60% and a negative net margin of 257.85%.

Tenon Medical Stock Performance

Shares of TNON opened at $1.74 on Wednesday. Tenon Medical has a 52-week low of $1.57 and a 52-week high of $45.50. The stock has a market capitalization of $4.68 million, a price-to-earnings ratio of -0.04 and a beta of 1.43. The stock’s 50-day simple moving average is $3.15 and its 200 day simple moving average is $16.04.

Insider Activity at Tenon Medical

In other news, major shareholder Financial Lp Hrt purchased 67,925 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was bought at an average cost of $3.63 per share, for a total transaction of $246,567.75. Following the acquisition, the insider directly owned 15,839 shares of the company’s stock, valued at $57,495.57. This represents a -130.41% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have acquired 129,945 shares of company stock valued at $500,468 and have sold 136,599 shares valued at $605,467. 17.71% of the stock is currently owned by insiders.

Analyst Ratings Changes

TNON has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tenon Medical in a research note on Thursday, October 15th. Wall Street Zen cut shares of Tenon Medical from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tenon Medical presently has an average rating of “Hold”.

About Tenon Medical

Tenon Medical, Inc. (NASDAQ:TNON) is a medical device company focused on developing and commercializing technologies for the treatment of sacroiliac (SI) joint dysfunction. The SI joint connects the lower spine to the pelvis and can be a source of chronic lower-back and pelvic pain. The company’s primary product is the Catamaran SIJ Fusion System, a minimally invasive surgical system designed to stabilize and fuse the SI joint through a transfixation approach. The system uses a specialized implant and delivery instruments intended to support placement across the SI joint while addressing the underlying source of instability.